Axion Biosystems, Inc.

Axion Biosystems, Inc., a foreign-owned manufacturer of live-cell analysis instruments, supplies microelectrode array (MEA) systems, consumables, and related maintenance and repair services to federal biomedical and drug-development research agencies as a prime contractor on full-and-open purchase orders and single-award indefinite-delivery contracts, without set-aside designation across nearly all recent work.

Axion is headquartered in Atlanta, Georgia, and operates as a for-profit corporate entity classified under NAICS 333314 (Analytical Laboratory Instrument Manufacturing). The vendor competes almost exclusively on unrestricted, non-set-aside solicitations; across 96 recent prime awards, only two small-business set-asides appear, suggesting Axion does not pursue or hold SBA certifications and wins work on technical merit and brand specificity alone. The vendor maintains a single subcontract engagement (a March 2024 sub-award for MEA plate consumables under an option year), making it operationally a prime-focused vendor.

Axion's customer base concentrates heavily in health-research agencies. The top five funding agencies account for 75% of award count and 90% of combined potential value: the Food and Drug Administration leads with 25 awards valued at $3.2 million combined potential value, followed by the National Center for Advancing Translational Sciences (12 awards, $1.9 million), the National Institute on Drug Abuse (11 awards, $1.4 million), the Environmental Protection Agency Office of Research and Development (16 awards, $731 thousand), and Veterans Integrated Service Network 1 (8 awards, $343 thousand). The two rankings align closely; FDA dominates both volume and dollars, signaling sustained, recurring demand from a single customer rather than dollar concentration from a few large deals.

Axion's capability portfolio centers on Maestro Pro multielectrode array systems and ancillary products. Representative prime work includes a $317.9 million Maestro Multi-Well MEA system awarded by FDA on a sole-source basis in March 2023 (completion June 2026), a $669 thousand service agreement with NCATS for preventative maintenance and repairs of multiple MEA instruments and liquid-handling components in Rockville, Maryland (September 2023 to September 2024), a $302.4 thousand Maestro Pro MEA system purchase order from FDA awarded September 2026 (completion September 2028), and recurring consumables orders—$72 thousand for 48-well and 96-well CytoView MEA plates from NCATS (September 2022), $56.9 thousand for 48-well MEA plates from EPA under a total small-business set-aside (April 2025), and multiple $12–27 thousand maintenance and repair orders from NIEHS, NCATS, and FDA spanning 2022 through 2026. The IDV footprint consists of a single $600 thousand indefinite-delivery contract awarded by FDA on August 17, 2026, for MEA plate consumables (base year plus four option years through August 2031) with deliveries to Silver Spring, Maryland.

Recent activity shows modest volume—six awards in 2026 year-to-date, down from eight in 2022, suggesting flatness or slight decline—with only four awards completing in the next twenty-four months and carrying combined potential value of $377 thousand, presenting minimal recompete cliff exposure. Combined potential value across all 96 recent awards is $8.4 million, although obligated dollars total $13.7 million (164% of potential value), indicating substantial prior-year invoicing on mature delivery contracts and service agreements. Axion's work is nearly 100% prime (95 of 96 awards), concentrated in laboratory equipment supply and maintenance under PSC 6650 (Laboratory Equipment and Supplies) and PSC 7300 (Maintenance/Repair/Rebuild of Equipment), with negligible subcontracting activity and no apparent teaming relationships among the recent source data.